Table 4.
Summary of published prospective trials evaluating local consolidation therapy for histology-agnostic oligometastasis
| Trial/Sponsor | Reference | No. of Patients | Grade 3+ Toxicity | Median FU time, months | Median PFS time, months | Median OS time, years | Local Control Rate |
|---|---|---|---|---|---|---|---|
| Erasmus MC Cancer Institute | Nuyttens, 201531 | 30 | 17% | 36 | ~8 (NR) | ~3.3 (NR) | 77% |
| University of Chicago | Wong, 201632 | 61 | 3% | 28 | 5 | 2.4 | 44% |
| University of Pittsburgh Medical Center | Sutera, 201933 | 147 | 2% | 41 | NR | 3.5 | 75% |
| SABR-COMET | Palma, 202034 | 66 | 11% | 51 | 12 | 4.2 | 63% |
| SAFRON II | Siva, 202121 | 87 | 3% | 37 | 13, 14 | Not reached | 85% |
| NRG-BR001 | Chmura, 202135 | 35 | 20% | 23 | NR | Not reached | NR |
| Multi-center | Zelefsky, 202136 | 117 | NR | 52 | NR | NR | 85% |
| DESTROY | Mercier, 202124 | 90 | 0% | 17 | 15 | NR | 96% |
| EXTEND Lead-In | Present study | 49 | 4% | 38 | 13 | Not reached | 98% |
Abbreviations: NR, not reported; FU, follow-up; PFS, progression-free survival; OS, overall survival.